Cargando…

PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis

Although many studies have addressed the prognostic value of programmed cell death-ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic search of the PubMed, EMBASE, and Cochrane Library databases was performed to identify the correlation between PD-L1 expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Minghui, Li, Guoliang, Wang, Yanbo, Wang, Yan, Zhao, Shu, Haihong, Pu, Zhao, Hongli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578960/ https://www.ncbi.nlm.nih.gov/pubmed/28860576 http://dx.doi.org/10.1038/s41598-017-10925-7

Ejemplares similares

Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
por: Zhang, Minghui, et al.
Publicado: (2017)

Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms
por: Ma, Jianli, et al.
Publicado: (2018)

Prognostic significance of PD-L1 expression and (18)F-FDG PET/CT in surgical pulmonary squamous cell carcinoma
por: Zhang, Minghui, et al.
Publicado: (2017)

An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma
por: Zhang, Minghui, et al.
Publicado: (2019)

Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma
por: Pu, Haihong, et al.
Publicado: (2015)

CD8(+) T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma
por: Zhang, Minghui, et al.
Publicado: (2022)

The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients
por: Zhang, Minghui, et al.
Publicado: (2016)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
por: Ji, Mei, et al.
Publicado: (2015)

Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
por: Lan, Bo, et al.
Publicado: (2018)

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
por: Tanaka, Ichidai, et al.
Publicado: (2021)

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
por: Wenfan, Fu, et al.
Publicado: (2023)

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment
por: Zhao, Yanbin, et al.
Publicado: (2021)

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
por: Li, Wenjie, et al.
Publicado: (2023)

Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype
por: Pandey, Rahul Kumar, et al.
Publicado: (2022)

Correlation between PD-L1 expression and radiomic features in early-stage lung adenocarcinomas manifesting as ground-glass nodules
por: Shi, Wenjia, et al.
Publicado: (2022)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
por: Gao, Feng, et al.
Publicado: (2019)

PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China
por: Li, Caichen, et al.
Publicado: (2020)

The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis
por: Xiao, Bo-Ya, et al.
Publicado: (2020)

PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
por: Wu, Xiaodong, et al.
Publicado: (2020)

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1
por: Wu, Di, et al.
Publicado: (2020)

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
por: Jiang, Liyan, et al.
Publicado: (2017)

Computational Approaches to Prioritize Cancer Driver Missense Mutations
por: Zhao, Feiyang, et al.
Publicado: (2018)

Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue
por: Wang, Chin‐Chou, et al.
Publicado: (2021)

Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis
por: Kong, Defeng, et al.
Publicado: (2021)

Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials
por: Zhao, Qiuling, et al.
Publicado: (2018)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
por: Zhang, Libin, et al.
Publicado: (2021)

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
por: Zhu, Jue, et al.
Publicado: (2021)

Characterization of driver mutations in Chinese non-small cell lung cancer patients using a novel targeted sequencing panel
por: Zhao, Jing, et al.
Publicado: (2022)

Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
por: Jiang, Tao, et al.
Publicado: (2019)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
por: Larsen, Trine Vilsbøll, et al.
Publicado: (2019)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis
por: Hu, Zhi-Ying, et al.
Publicado: (2020)

AI-Driver: an ensemble method for identifying driver mutations in personal cancer genomes
por: Wang, Haoxuan, et al.
Publicado: (2020)

PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma
por: Chen, Zhenwen, et al.
Publicado: (2021)

The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis
por: Yang, Yilin, et al.
Publicado: (2020)

CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_304hb12nees1usdr7c090l730f